{"disease":{"id":"amd","name":"amd"},"drugs":{"marketed":[{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy (GA) secondary to AMD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05146687","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":369600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05110209","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":331541,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05066685","title":"Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program","phase":"","overall_status":"COMPLETED","enrollment_count":18457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05037396","title":"Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab","phase":"","overall_status":"COMPLETED","enrollment_count":9457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05082415","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":9456,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05111743","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":9261,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02194803","title":"Observation of Treatment Patterns With Lucentis in Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5778,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07069647","title":"Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":4300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04390126","title":"COVID-19 Related Lockdown Effects On Chronic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":1343,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT07084883","title":"Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":1076,"lead_sponsor_name":"iHealthScreen Inc","has_results":false},{"nct_id":"NCT05698316","title":"A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Association for Innovation and Biomedical Research on Light and Image","has_results":false},{"nct_id":"NCT06843499","title":"Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06541704","title":"A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":975,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT01432847","title":"Cell Collection to Study Eye Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT07516132","title":"Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03349801","title":"Development of Novel Clinical Endpoints in Intermediate AMD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":718,"lead_sponsor_name":"Frank G. Holz","has_results":false},{"nct_id":"NCT03367767","title":"Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On","phase":"","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT00647439","title":"Genetics and Markers of Degenerative and Inflammatory Eye Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03577041","title":"Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04270747","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02103738","title":"Canadian Treat and Extend Analysis Trial With Ranibizumab","phase":"","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04657289","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":451,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07269769","title":"A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Tasly Pharmaceutical Group Co., Ltd","has_results":false},{"nct_id":"NCT05155293","title":"Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"Alvotech Swiss AG","has_results":false},{"nct_id":"NCT01972789","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01778491","title":"AMD Phenotype and Genotype Study","phase":"","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT07305298","title":"Mirabegron in Patients With Age-Related Macular Degeneration","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":312,"lead_sponsor_name":"University of Naples","has_results":false},{"nct_id":"NCT07216677","title":"A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Interstat LLC","has_results":false},{"nct_id":"NCT03969303","title":"NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients","phase":"","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Notal Vision Ltd.","has_results":false},{"nct_id":"NCT07482176","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06856577","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06795048","title":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":274,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06493136","title":"Etude de l'ANesthésie Par Gel de Lidocaïne Pour Les Injections IntrA vitréennes","phase":"","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Institut Ophtalmologique de l'Ouest Jules Verne","has_results":false},{"nct_id":"NCT05481827","title":"ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":225,"lead_sponsor_name":"Gyroscope Therapeutics Limited","has_results":false},{"nct_id":"NCT07170683","title":"Microperimetry Changes in Retinal Function in Macular Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03845582","title":"Phase 2/3 Study of ALK-001 in Geographic Atrophy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Alkeus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03690505","title":"Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT07185841","title":"Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Fujian Haixi Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03372746","title":"Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06116890","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT07365371","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04177069","title":"Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"VISUfarma SpA","has_results":false},{"nct_id":"NCT01542866","title":"A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07205887","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"EyeBiotech Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}